Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Shares Outstanding (Weighted Average) (2017 - 2025)

Crinetics Pharmaceuticals has reported Shares Outstanding (Weighted Average) over the past 9 years, most recently at $94.1 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 16.43% year-over-year to $94.1 million; the TTM value through Dec 2025 reached $94.1 million, up 16.43%, while the annual FY2025 figure was $94.1 million, 16.43% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $94.1 million at Crinetics Pharmaceuticals, roughly flat from $94.2 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $94.2 million in Q3 2025 and troughed at $33.0 million in Q1 2021.
  • A 5-year average of $62.5 million and a median of $54.5 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): surged 44.53% in 2022 and later increased 7.1% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $38.4 million in 2021, then soared by 35.24% to $52.0 million in 2022, then grew by 11.71% to $58.1 million in 2023, then soared by 39.11% to $80.8 million in 2024, then grew by 16.43% to $94.1 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CRNX at $94.1 million in Q4 2025, $94.2 million in Q3 2025, and $93.8 million in Q2 2025.